生命科学资讯

Editor's Corner: Fierce Biotech’s 10 most-read stories of 2025

Edwards nets FDA approval for Sapien M3 transcatheter mitral valve replacement

Tela Bio sues BD over hernia mesh monopoly claims

Windtree offloads cardio pipeline, Vaccinex secures $60M funding in continued holiday shopping spree

Despite geopolitical pressures, China biotech deals remain at pace as collective value soars: Evaluate

Hope springs toward Parkinson's phase 3 despite divergent stem cell therapy data

The top 5 stock picks for biotech in 2026: William Blair

Miracle babies, antibiotic improv and T-cell tamers: Fierce's favorite research stories of 2025

6 people charged in $41M insider trading scheme tied to 2 biotechs

BioMarin quietly discards liver disease candidate after $4.8B Amicus announcement

Abbott’s Volt pulsed field ablation system scores FDA approval

Big Pharma-backed Aktis plans IPO to fund radiopharma trials

Boehringer spells out a $448M future for Rectify's ABC kidney disease program

Hologic breast cancer study bolsters use of mammogram AI

Editor's corner: Fierce Medtech's top 10 stories of 2025 show how tech can treat

Gilead pays $35M to license pair of HSV assets from Assembly Bio pact

AstraZeneca fronts $100M for Jacobio's clinical-stage pan-KRAS inhibitor

AstraZeneca flunks phase 3 lung cancer test in further setback to synthetic lethal mechanism

Looking ahead with BD’s Bilal Muhsin on what good AI can still do for healthcare

Ipsen's hopes for next-gen rare disease drug dashed by pivotal phase 2 fail